Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

Abstract: The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.

Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.

Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.

Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.

Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single do main antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.

Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.

Abstract: The present invention relates to a fragment antigen-binding (Fab) fragment specifically binding to epidermal growth factor receptor (EGFR), an expression construct for preparing the Fab fragment, a method for preparing the Fab fragment, and a pharmaceutical composition containing the Fab fragment. The Fab fragment to EGFR of the present invention is smaller than the antibody, and thus can favorably permeate into tissues or tumors and can be prepared in bacteria, resulting in low production costs. Furthermore, the Fab fragment to EGFR of the present invention has an increased in vivo half-life through pegylation.

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing cell surface VCAM-1 activity in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Abstract: The present invention relates to a cellular immunotherapy for treatment of tumors, particularly to a peptide of a chimeric antigen receptor hCD87-CAR and the applications thereof, the peptide of said antigen receptor being carried by a vector packaged in a lentivirus. The chimeric antigen receptor hCD87-CAR contains a fragment of anti CD87 monoclonal antibody hCD87scFv consisting of a sequence selected from a peptide comprising: (a) SEQ ID NO. 1 or SEQ ID NO. 2; (b) a peptide having the same function as the sequence of (a); and (c) a peptide having at least 90% homology to the sequence of (a). The hCD87-CAR is used for modifying T lymphocytes, and the modified T cells (CAR-T cells) can be used for the therapy of tumors that are cell surface CD87-positive.

Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

Abstract: Disclosed are binding proteins, or fragments thereof, that specifically binds to a cancer-specific glycosylation variant of a protein and to a second epitope on the same protein, to a different protein presented on the same cell, or to a different protein presented on a different cell, such as an encoded polypeptide binding to both a cancer cell and an activated T cell. Also disclosed are polynucleotides encoding such binding proteins, including polynucleotides comprising codon-optimized coding regions and polynucleotides comprising coding regions that are not codon-optimized for expression in a particular host cell. Also disclosed are methods of making the encoded polypeptide and methods of using the polypeptide to treat, prevent or ameliorate the symptom of a disease such as cancer.

Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Abstract: The invention provides anti-Factor D antibodies and conjugates and methods of using the same.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.

Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.

Abstract: Disclosed is an apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule (s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.

Abstract: A method of disintegrating pulp for use in cellulose acetate production includes: a primary disintegration step of disintegrating a pulp sheet into pulp pieces having an average area of not more than 45 cm2; and a secondary disintegration step of disintegrating the pulp pieces with an impact shock exerted by a jet mill (20). The jet mill (20) includes: a cylindrical casing (21) provided with an inlet (21d) and an outlet (21e); and a rotor (25) including a plurality of blades (25a) provided on its outer peripheral portion, the plurality of blades (25a) facing an inner peripheral surface of the casing (21).

Abstract: The present invention relates to a method for manufacturing cellulose carbamate which method comprises the following steps: providing a never-dried pulp, adding urea and mixing said pulp with said urea, mechanically treating said mixture, drying the mixture, and heating the relatively dry mixture thus providing a cellulose carbamate. The present invention also relates to a cellulose carbamate obtainable by said method, use of said cellulose carbamate and a dope comprising said cellulose carbamate.

Abstract: The subject matter of the invention is dextrans which have between 95% and 99% of ?-1,6 glucosidic bonds, a weight-average molar mass Mw at least equal to 0.7×109 g.mol?1, and a dispersity index D of between 1.3 and 3. The invention also relates to a dextran saccharase which makes it possible to produce such dextrans, and to a method for producing said dextrans.

Abstract: Provided is an ?-aminoalkylphenone compound that has good stability and low sublimability, efficiently generates radicals when irradiated with a bright line at 365 nm (I line) or the like, and is useful as a polymerization initiator to be used in a radically polymerizable composition. The ?-aminoalkylphenone compound is represented by Formula (I) mentioned below. In Formula (I) mentioned above, it is preferable that R11 is a nitro group, an alkoxy group having 1 to 12 carbon atoms, or an alkoxycarbonyl group having 1 to 12 carbon atoms. The ?-aminoalkylphenone compound can be preferably used in a polymerization initiator.

Abstract: The present invention relates to a novel ligand compound, a transition metal compound and a catalyst composition including the transition metal compound. The novel ligand compound and the transition metal compound of the present invention may be usefully used as the catalyst of a polymerization reaction for preparing an olefin polymer having a low density relative to a CGC catalyst. In addition, a product having a low melt index (MI) and a high molecular weight may be manufactured using the olefin polymer polymerized using the catalyst composition including the transition metal compound.

Abstract: Disclosed herein are ethylene-based polymers produced using dual metallocene catalyst systems. These polymers have low densities, high molecular weights, and broad molecular weight distributions, as well as having the majority of the long chain branches in the lower molecular weight component of the polymer, and the majority of the short chain branches in the higher molecular weight component of the polymer. Films produced from these polymers have improved impact and puncture resistance.

Abstract: A polymer having a long chain branching content peaking at greater than about 20 long chain branches per million carbon atoms, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 8 long chain branches per million carbon atoms, a polydispersity index of greater than about 20 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 1 long chain branches per chain, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution.

Abstract: A process for component separation in a polymer production system, comprising separating a polymerization product stream into a gas stream and a polymer stream, wherein the gas stream comprises ethane and unreacted ethylene, distilling the gas stream into a light hydrocarbon stream, wherein the light hydrocarbon stream comprises ethane and unreacted ethylene, contacting the light hydrocarbon stream with an absorption solvent system, wherein at least a portion of the unreacted ethylene from the light hydrocarbon stream is absorbed by the absorption solvent system, and recovering a waste gas stream from the absorption solvent system, wherein the waste gas stream comprises ethane, hydrogen, or combinations thereof.

Abstract: In one aspect, the present invention encompasses safe and efficient methods for providing highly pure acrylic acid. In certain embodiments, the inventive methods include the step of producing polypropiolactone from ethylene oxide at a first location, transporting the polymer to a second location and pyrolyzing the polypropiolactone to provide glacial acrylic acid. In certain embodiments, the step of pyrolyzing the polymer is performed continuously in conjunction with a polymerization process to make SAPs.

Abstract: This invention relates to a process for forming a long-chain branched polymer and a long-chain branched polymer resulting from the process. The process comprises reacting (a) a polyolefin base polymer with (b) a coupling agent comprising a polymeric coupling agent, optionally blended with a molecular coupling agent, the polymeric coupling agent being a modified polyolefin having a reactive coupling group at one or more terminal ends of the modified polyolefin chain, to couple the polyolefin base polymer (a) with the coupling agent (b) to form a long-chain branched polymer having a long-chain branching and/or higher surface energy relative to the polyolefin base polymer.

Abstract: The invention relates to a process for the preparation of ethylene-propylene copolymers having —a weight average molecular weight of 800,000-1,800,000, —a molecular weight distribution of 3-8, —an ethylene content of 1-10 wt %, preferably 1.5 to 5.5 wt %. —a melt flow in the range of 1.5-8 dg/min measured with a load of 21.6 kg at 230° C. and —a xylene soluble content of 2-15 wt % by converting propylene into the UHMWEP copolymer without pre-polymerization in the presence of a polymerization catalyst under a condition where the volume ratio of H2 to propylene is at most 0.

Abstract: This disclosure relates to a process for polymerization, and in particular to minimizing undesired polymerization reactions downstream of a polymerization reaction zone, for instance by use of a quenching agent that enables fast reaction rates with active polymerization catalyst in the polymerization effluent, so as to quench the catalyst quickly, thereby preventing uncontrolled polymerization reactions. A preferred quenching agent is methanol. Also provided are means for treating polymer recycle streams containing oxygenates, which may result from the use of such quench agents, particularly in polymerization processes including polyene (e.g., diene) monomers.

Abstract: A method of producing ultra high molecular weight (UHMW) C4-C30 ?-olefin drag reducing agent (DRA). The method includes polymerizing in a reactor a first ?-olefin monomer in the presence of catalyst and hydrocarbon solvent to produce the DRA. The catalyst consists essentially of at least one tertiary monophenyl amine having a formula R1R2N-aryl, where R1 and R2 are the same or different, and each is a hydrogen, an alkyl, or a cycloalkyl group, where at least one of R1 and R2 contain at least one carbon atom; at least one titanium halide having a formula TiXm, where m is from 2.5 to 4.0 and X is a halogen containing moiety; and at least one cocatalyst having a formula AlRnY3-n where R is a hydrocarbon radical, Y is a halogen or hydrogen, and n is 1-20. Further, the catalyst is absent of a carrier or support.

Abstract: A method of crosslinking a polyolefin resin with a silyl hydride crosslinking agent is disclosed. Crosslinkable compositions containing a polyolefin resin having about 0.9% to about 10% diene groups and a silyl hydride crosslinking agent are also disclosed.

Abstract: Disclosed are copolymers formed by copolymerization of: (1) one or more hydrofluoroolefin monomer(s) selected from the group consisting of hydrofluoroethylenes, hydrofluoropropenes, hydrofluorobutenes, hydrofluoropentenes and combinations of these, and preferably selected from 2,3,3,3-tetrafluoropropene, 1,3,3,3-tetrafluoropropene, with said 1,3,3,3-tetrafluoropropene preferably comprising, consisting essentially of or consisting of trans-1,3,3,3-tetrafluoropropene, and combinations of these, and (2) one or more chlorofluoroethylene monomers, preferably chlorotrifluoroethylene (“CTFE”) monomers, wherein the mole ratio of monomer (1) to monomer (2) is preferably from about 30:1 to about 1:30.

Abstract: New molecularly imprinted polymers are described, and a method for their production using novel particle technology based on multifunctional placeholder templates.

Abstract: A copolymer is provided, which includes a chemical structure of: R is C1-6 alkylene group. T is a terminal group including C1-6 alkyl group, C3-6 cycloalkyl group, or C6-12 aromatic group. l is 0.05 to 0.3, m is 0.1 to 0.2, n is 0.5 to 0.8, l+m+n=1, x is 40 to 100, and o is 10 to 120. An epoxy resin composite is also provided, which includes 100 parts by weight of epoxy resin and 1 to 20 parts by weight of toughness enhancer such as the above copolymer.

Abstract: The purpose of the present invention is to provide: a cross-copolymer in which a residual catalyst component remains in a reduced amount and which has improved transparency, applicability to medical materials and yellowish discoloration resistance; and a method for producing the cross-copolymer.

Abstract: The present invention provides resin compositions for golf balls which have excellent flexibility, fluidity, and resilience, and golf balls formed from the resin compositions. The present invention relates to a resin composition for golf balls including a polymer that contains a diene polymer moiety and a carboxylic acid-based moiety wherein carboxyl groups derived from the carboxylic acid-based moiety are neutralized.

Abstract: Provided is a photocurable resin composition that has a low viscosity and is capable of yielding a high refractive index. Specifically, a urethane (meth)acrylate resin (A) obtained by a reaction of an aromatic diisocyanate compound (a), a polyol compound (b), and a hydroxyl-group-containing (meth)acrylate compound (c) as essential raw material components is used. The urethane (meth)acrylate resin (A) contains a structural moiety (a-1) represented by structural formula (1) below: (where R1 represents a hydrogen atom or a methyl group) and a structural moiety (a-2) represented by structural formula (2) below: (where R1, R2, R3, X1, and X2 each independently represent a hydrogen atom or a methyl group) at a (a-1)/(a-2) molar ratio of 45/55 to 60/40. The polyol compound (b) has an aromatic hydrocarbon skeleton.

Abstract: The invention provides new water soluble polymers for the use in industrial processes, where large quantities of water is handled, such as sludge dewatering and papermaking. These new polymers are water soluble cross-linked block copolymers, wherein the block copolymers are cross-linked together using a cross-linking agent. Each of the block copolymers contain two different blocks, and these blocks are formed from different monomers. The blocks are linked together with a molecular spacer derived from a bifunctional initiator used during the polymerization of the blocks. The monomers used in polymerizing the blocks are different with each other and they are selected from a group consisting of N-vinylformamide, acrylic acid, acrylamide and water-soluble derivatives thereof.

Abstract: Crosslinkable random copolymers comprising atom transfer radical polymerization (ATRP) initiators and crosslinked copolymer films formed from the copolymers are provided. The random copolymers, which are polymerized from one or more alkyl halide functional inimers and one or more monomers having a crosslinkable functionality, are characterized by pendant ATRP initiating groups and pendant crosslinkable groups.